ICLUSIG (ponatinib) patient profiles in Ph+ ALL

Watch for patients with TKI resistance/intolerance or known mutations, such as T315I

ICLUSIG may benefit specific types of patients with Ph+ ALL

Jamal with Ph+ ALL.

Jamala | 35

Risk factors:
Hyperlipidemia (controlled)

Single point mutation detected (E255K)

Prior Course of Treatment:
Patient discontinued dasatinib with steroid therapy due to dasatinib intolerance

Sandra with Ph+ ALL.

Sandraa | 61

Risk factors:
Hypertension (controlled)

No additional mutations detected 

Prior Course of Treatment:
Patient tested positive for the T315I mutation while on dasatinib 

aHypothetical patient profiles

ICLUSIG demonstrated efficacy in

ICLUSIG has a simple dosing schedule

Ph+ ALL=Philadelphia chromosome positive acute lymphoblastic leukemia; TKI=Tyrosine kinase inhibitor.